Seaport Res Ptn Boosts Earnings Estimates for Aspen Aerogels

Key Points

• Seaport Res Ptn has increased its Q3 2025 earnings per share estimate for Aspen Aerogels from a loss of $0.05 to a profit of $0.02.
• Aspen Aerogels reported a quarterly earnings result of ($0.04) EPS, beating expectations by $0.08, despite a 33.8% year-over-year revenue decline to $78.02 million.
• The company's stock has seen significant analyst activity, with ratings spanning from "buy" to "underweight," and a current average price target of $19.50.

Aspen Aerogels, Inc. (NYSE:ASPN - Free Report) - Investment analysts at Seaport Res Ptn raised their Q3 2025 earnings estimates for Aspen Aerogels in a research report issued to clients and investors on Wednesday, August 13th. Seaport Res Ptn analyst T. Curran now expects that the construction company will earn $0.02 per share for the quarter, up from their prior estimate of ($0.05). The consensus estimate for Aspen Aerogels' current full-year earnings is $0.17 per share. Seaport Res Ptn also issued estimates for Aspen Aerogels' Q4 2025 earnings at $0.02 EPS, FY2025 earnings at ($0.06) EPS, Q1 2026 earnings at ($0.04) EPS, Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at $0.03 EPS, Q4 2026 earnings at $0.06 EPS, FY2026 earnings at $0.02 EPS and FY2027 earnings at $0.44 EPS.

ASPN has been the topic of a number of other reports. Barclays cut shares of Aspen Aerogels from an "equal weight" rating to an "underweight" rating and increased their target price for the stock from $7.00 to $16.00 in a report on Monday, August 11th. Canaccord Genuity Group lowered their price target on shares of Aspen Aerogels from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Finally, Oppenheimer cut shares of Aspen Aerogels from an "outperform" rating to a "market perform" rating in a report on Thursday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $19.50.

Aspen Aerogels Stock Performance

Shares of NYSE:ASPN traded up $0.3350 on Monday, reaching $6.9750. 1,651,167 shares of the company's stock were exchanged, compared to its average volume of 2,794,713. The firm has a market capitalization of $574.46 million, a price-to-earnings ratio of -1.83 and a beta of 2.73. Aspen Aerogels has a fifty-two week low of $4.16 and a fifty-two week high of $32.31. The business's 50-day moving average is $6.91 and its two-hundred day moving average is $6.79. The company has a quick ratio of 3.31, a current ratio of 3.98 and a debt-to-equity ratio of 0.34.

Aspen Aerogels (NYSE:ASPN - Get Free Report) last issued its earnings results on Thursday, August 7th. The construction company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.12) by $0.08. The company had revenue of $78.02 million for the quarter, compared to analysts' expectations of $72.53 million. Aspen Aerogels had a negative net margin of 78.53% and a positive return on equity of 2.92%. The firm's revenue was down 33.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.21 earnings per share. Aspen Aerogels has set its FY 2025 guidance at -3.860--3.730 EPS.

Insider Buying and Selling at Aspen Aerogels

In related news, CAO Santhosh P. Daniel sold 4,410 shares of the stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $7.31, for a total value of $32,237.10. Following the sale, the chief accounting officer owned 19,879 shares of the company's stock, valued at $145,315.49. This trade represents a 18.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Aspen Aerogels

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Caxton Associates LLP grew its position in Aspen Aerogels by 114.9% in the 2nd quarter. Caxton Associates LLP now owns 103,172 shares of the construction company's stock valued at $611,000 after buying an additional 55,167 shares in the last quarter. FORA Capital LLC boosted its holdings in shares of Aspen Aerogels by 138.2% in the second quarter. FORA Capital LLC now owns 29,452 shares of the construction company's stock valued at $174,000 after acquiring an additional 17,090 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Aspen Aerogels by 184.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,235 shares of the construction company's stock valued at $43,000 after acquiring an additional 4,693 shares in the last quarter. Voleon Capital Management LP increased its stake in shares of Aspen Aerogels by 464.8% during the second quarter. Voleon Capital Management LP now owns 248,839 shares of the construction company's stock valued at $1,473,000 after acquiring an additional 204,779 shares during the period. Finally, HRT Financial LP increased its stake in shares of Aspen Aerogels by 668.7% during the second quarter. HRT Financial LP now owns 595,742 shares of the construction company's stock valued at $3,526,000 after acquiring an additional 518,243 shares during the period. Institutional investors own 97.64% of the company's stock.

About Aspen Aerogels

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.